A Real World Study of Sacituzumab Govitecan

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

NCT04001634 ·Status: COMPLETED

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

NCT04454437 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Real World Study on the Efficacy and Safety of Anti-HER2 Therapy

NCT05367739 ·Status: COMPLETED

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

NCT04639986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

NCT06993506 ·Status: NOT_YET_RECRUITING

Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients

NCT01658033 ·Status: COMPLETED ·Phase: PHASE2

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

NCT05769751 ·Status: COMPLETED

Fulvestrant 500mg in Patients With Advanced Breast Cancer

NCT02909361 ·Status: UNKNOWN

Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients

NCT05839288 ·Status: COMPLETED

Sacituzumab Govitecan In TNBC

NCT04230109 ·Status: RECRUITING ·Phase: PHASE2

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

NCT03695341 ·Status: COMPLETED

Reverse HER2-negative Immune Resistant Breast Cancer

NCT06731140 ·Status: RECRUITING ·Phase: PHASE2

Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment

NCT06914661 ·Status: ENROLLING_BY_INVITATION

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

NCT06926920 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients

NCT03541863 ·Status: COMPLETED

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

NCT05263570 ·Status: RECRUITING

Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

NCT04158505 ·Status: UNKNOWN

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

NCT05675579 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer

NCT06578299 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

NCT06344780 ·Status: ACTIVE_NOT_RECRUITING

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

NCT04263298 ·Status: RECRUITING ·Phase: PHASE3

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

NCT04595565 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

NCT06341621 ·Status: RECRUITING ·Phase: PHASE3

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

NCT06954961 ·Status: RECRUITING ·Phase: PHASE3